Prowess-shock trial: A protocol overview and perspectives

Shock

Volumn 34, Issue SUPPL. 1, 2010, Pages 48-53

  Silva, Eliézer ^a   De Figueiredo, Luiz Francisco Poli ^b   Colombari, Fernando ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

activated protein C; Clinical trials; drotrecogin alpha activated; inflammation; shock septic; survival

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; HYPERTENSIVE AGENT; PLACEBO; PROTEIN S;

ANTIINFLAMMATORY ACTIVITY; APACHE; BLEEDING; BLOOD CLOTTING TEST; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; FIBROSIS; HIGH RISK PATIENT; HUMAN; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SEPSIS; THROMBOSIS;

ADULT; ANIMALS; APACHE; BLOOD COAGULATION FACTORS; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; EUROPE; FIBRINOLYSIS; HEALTH PROMOTION; HUMANS; INFLAMMATION; INTERNATIONAL COOPERATION; MULTICENTER STUDIES AS TOPIC; MULTIPLE ORGAN FAILURE; PROTEIN C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RESEARCH DESIGN; SHOCK, SEPTIC; THROMBOPHILIA; UNITED STATES;

EID: 77955980902     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181e7e97b     Document Type: Review

References (45)

1. Schmid A, Burchardi H, Clouth J, Schneider H: Burden of illness imposed by severe sepsis in Germany. Eur J Health Econ 3(2):77-82, 2002
2. Sogayar AM, Machado FR, Rea-Neto A, Dornas A, Grion CM, Lobo SM, Tura BR, Silva CL, Cal RG, Beer I, et al.: A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmaco-economics 26(5):425-434, 2008
3. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, et al.: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360(13):1283-1297, 2009
4. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19):1368-1377, 2001
5. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, et al.: Hydrocortisone therapy for patients with septic shock. N Engl J Med 358(2):111-124, 2008
6. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699-709, 2001
7. Levi M, Ten Cate H: Disseminated intravascular coagulation. N Engl J Med 341(8):586-592, 1999
8. Levi M, van der Poll T, Buller HR: Bidirectional relation between inflammation and coagulation. Circulation 109(22):2698-2704, 2004
9. Esmon CT: Role of coagulation inhibitors in inflammation. Thromb Haemost 86(1):51-56, 2001
10. Levi M, de Jonge E, van der Poll T: Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 29(7 Suppl):S90YS94, 2001
11. EsmonCT: The regulation of natural anticoagulant pathways. Science 235(4794): 1348-1352, 1987
12. Esmon CT: The endothelial cell protein C receptor. Thromb Haemost 83(5): 639-643, 2000
13. Mesters RM, Helterbrand J, Utterback BG, Yan B, Chao YB, Fernandez JA, Griffin JH, Hartman DL: Prognostic value of protein C concentrations in neu-tropenic patients at high risk of severe septic complications. Crit Care Med 28(7):2209-2216, 2000
14. Vary TC, Kimball SR: Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol 262(2 Pt 1):C445YC452, 1992
15. Eckle I, Seitz R, Egbring R, Kolb G, Havemann K: Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler 372(11):1007-1013, 1991
16. Nawroth PP, Stern DM: Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163(3):740-745, 1986
17. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS: Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345(6):408-416, 2001
18. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79(3):918-925, 1987
19. De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent JL: Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med 34(7):1918-1924, 2006
20. Gruber A, Harker LA, Hanson SR, Kelly AB, Griffin JH: Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation 84(6):2454-2462, 1991
21. Gruber A, Marzec UM, Bush L, Di Cera E, Fernandez JA, Berny MA, Tucker EI, McCarty OJ, Griffin JH, Hanson SR: Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood 109(9):3733-3740, 2007
22. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, Kosanke S, Peer G, Esmon CT: The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 95(5): 1680-1686, 2000
23. Hancock WW, Grey ST, Hau L, Akalin E, Orthner C, Sayegh MH, Salem HH: Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 60(12):1525-1532, 1995
24. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, O'Neill L, Kelleher D, Schwarz HP, Smith OP: Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 110(1):130-134, 2000
25. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G 3rd, Bernard GR: Effects of drotrecogin alfa (activated) on organ dysfunction in the Prowess trial. Crit Care Med 31(3):834-840, 2003
26. Ely EW, Angus DC, Williams MD, Bates B, Qualy R, Bernard GR: Dro-trecogin alfa (activated) treatment of older patients with severe sepsis. Clin Infect Dis 37(2):187-195, 2003
27. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF: Severe community-acquired pneumonia as a cause of severe sepsis: data from the Prowess study. Crit Care Med 33(5): 952-961, 2005
28. Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan SB, Williams MD, Graham DE, et al.: Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 37(1):50-58, 2003
29. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, et al.: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial enhance: further evidence for survival and safety and implications for early treatment. Crit Care Med 33(10):2266-2277, 2005
30. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353(13): 1332-1341, 2005
31. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, et al.: Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 369(9564):836-843, 2007
32. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36(1):296-327, 2008
33. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, et al.: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 176(5):483-490, 2007
34. Kanji S, Perreault MM, Chant C, Williamson D, Burry L: Evaluating the use of drotrecogin alfa (activated) in adult severe sepsis: A Canadian multicenter observational study. Intensive Care Med 33(3):517-523, 2007
35. Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D: Use of dro-trecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 33(3):426-434, 2007
36. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, Sundin DP, Levi M: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2(11):1924-1933, 2004
37. Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, Williams MD: Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 33(10):2194-2201, 2005
38. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31(4):1250-1256, 2003
39. Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R: PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med 37(2):456-462, 2009
40. Lisboa T, Diaz E, Sa-Borges M, Socias A, Sole-Violan J, Rodriguez A, Rello J: The ventilator-associated pneumonia PIRO score: A tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia. Chest 134(6):1208-1216, 2008
41. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31(1):12-19, 2003
42. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF: Effects of drotrecogin alfa (activated) in human endo-toxemia. Shock 21(3):222-229, 2004
43. Colin G, Annane D: Corticosteroids and human recombinant activated protein C for septic shock. Clin Chest Med 29(4):705-712, 2008
44. Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Gardlund B, Marshall JC, Rhodes A: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 34(11):1935-1947, 2008
45. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, et al.: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104(13):3878-3885, 2004